9 0.68 (8.17%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 10.99 | 1-year : | 12.39 |
Resists | First : | 9.41 | Second : | 10.6 |
Pivot price | 8.46 | |||
Supports | First : | 7.48 | Second : | 6.22 |
MAs | MA(5) : | 8.33 | MA(20) : | 8.77 |
MA(100) : | 8.42 | MA(250) : | 7.44 | |
MACD | MACD : | -0.3 | Signal : | -0.3 |
%K %D | K(14,3) : | 37.7 | D(3) : | 29.3 |
RSI | RSI(14): 53.5 | |||
52-week | High : | 16.39 | Low : | 5.19 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ONCT ] has closed below upper band by 28.8%. Bollinger Bands are 21% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 9.26 - 9.29 | 9.29 - 9.34 |
Low: | 7.91 - 7.95 | 7.95 - 7.99 |
Close: | 8.93 - 8.99 | 8.99 - 9.06 |
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.
Sun, 10 Mar 2024
Oncternal Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line - Simply Wall St
Fri, 08 Mar 2024
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2023 Earnings Call Transcript - Yahoo Finance
Thu, 07 Mar 2024
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results - GlobeNewswire
Thu, 07 Mar 2024
Oncternal Therapeutics, Inc. (ONCT) Q4 2023 Earnings Call Transcript - Seeking Alpha
Thu, 07 Mar 2024
Oncternal Therapeutics: Q4 Earnings Snapshot - Quartz
Sun, 03 Mar 2024
Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth? - Simply Wall St
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 3 (M) |
Held by Insiders | 2.66e+006 (%) |
Held by Institutions | 8.4 (%) |
Shares Short | 25 (K) |
Shares Short P.Month | 0 (K) |
EPS | 0 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -3 % |
Return on Assets (ttm) | 244.4 % |
Return on Equity (ttm) | -49.5 % |
Qtrly Rev. Growth | 785000 % |
Gross Profit (p.s.) | 53.79 |
Sales Per Share | -63.33 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -13.5 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -32 (M) |
PE Ratio | 0 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.15 |
Price to Cash Flow | 1.21 |
Dividend | 0 |
Forward Dividend | 16040 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |